WEBULL
News
PHVS
26.42
+5.09%
1.28
Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)
TipRanks · 6d ago
Weekly Report: what happened at PHVS last week (0126-0130)?
Weekly Report · 6d ago
Bank of America Securities Keeps Their Hold Rating on Pharvaris (PHVS)
TipRanks · 01/27 13:28
Assessing Pharvaris (PHVS) Valuation After Earnings Beat And Renewed Analyst Optimism
Simply Wall St · 01/27 03:25
Analysts Conflicted on These Healthcare Names: Galapagos (GLPG), Pharvaris (PHVS) and Stevanato Group (STVN)
TipRanks · 01/26 13:21
Weekly Report: what happened at PHVS last week (0119-0123)?
Weekly Report · 01/26 09:03
Weekly Report: what happened at PHVS last week (0112-0116)?
Weekly Report · 01/19 09:03
A Look At Pharvaris (PHVS) Valuation As Long Term Returns Contrast With Current Price To Book Metrics
Simply Wall St · 01/15 15:24
Pharvaris (PHVS) Receives a Buy from Leerink Partners
TipRanks · 01/13 14:25
Pharvaris: Multiple Late‑Stage Catalysts, Differentiated Oral HAE Franchise, and Solid Cash Runway Support Buy Rating and $48 Target
TipRanks · 01/12 22:05
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts
TipRanks · 01/12 12:17
Pharvaris joins Nasdaq Biotechnology Index
Reuters · 01/12 11:50
PHARVARIS OUTLINES 2026 STRATEGIC PRIORITIES
Reuters · 01/12 11:50
Weekly Report: what happened at PHVS last week (0105-0109)?
Weekly Report · 01/12 09:03
Oppenheimer’s best small and mid-cap ideas for 2026
Seeking Alpha · 01/06 16:59
Weekly Report: what happened at PHVS last week (1229-0102)?
Weekly Report · 01/05 09:03
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and Pharvaris (PHVS)
TipRanks · 01/04 09:10
Weekly Report: what happened at PHVS last week (1222-1226)?
Weekly Report · 12/29/2025 09:03
Why Pharvaris (PHVS) Is Up 13.3% After RAPIDe-3 Success And 2026 Deucrictibant Filing Plans
Simply Wall St · 12/23/2025 03:22
Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)
TipRanks · 12/22/2025 14:06
More
Webull provides a variety of real-time PHVS stock news. You can receive the latest news about Pharvaris N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHVS
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.